SrasV1, PascalFrancis, Curation, bibRecord, 000567

Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design

Identifieur interne : 000567 ( PascalFrancis/Curation ); précédent : 000566; suivant : 000568

Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design

Auteurs : HAITAO YANG [République populaire de Chine] ; Mark Bartlam ; ZIHE RAO

Source :

Current pharmaceutical design [ 1381-6128 ] ; 2006.

RBID : Pascal:07-0053593

Descripteurs français

Pascal (Inist)
- Médicament, Cible, Ciblage, Peptidases, Coronavirus, Article synthèse, Antiviral, Conception, Recherche développement, Syndrome respiratoire aigu sévère, Inhibiteur enzyme, Structure moléculaire.
Wicri :
- topic : Médicament.

English descriptors

KwdEn :
- Antiviral, Coronavirus, Design, Drug, Enzyme inhibitor, Molecular structure, Peptidases, Research and development, Review, Severe acute respiratory syndrome, Target, Targeting.

Abstract

Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M^pro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M^pros. It is expected that inhibitors targeting CoV M^pros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.

A01	`01`	`1`		`@0 1381-6128`
A03		`1`		`@0 Curr. pharm. des.`
A05				`@2 12`
A06				`@2 35`
A08	`01`	`1`	`ENG`	`@1 Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design`
A11	`01`	`1`		`@1 HAITAO YANG`
A11	`02`	`1`		`@1 BARTLAM (Mark)`
A11	`03`	`1`		`@1 ZIHE RAO`
A14	`01`			`@1 National Laboratory of Biomacromolecules, Institute of Biophysics (IBP), Chinese Academy of Sciences @2 Beijing 100101 @3 CHN`
A14	`02`			`@1 Tsinghua-IBP Joint Research Group for Structural Biology, Tsinghua University @2 Beijing 100084 @3 CHN`
A20				`@1 4573-4590`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 26320 @5 354000145201350040`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 131 ref.`
A47	`01`	`1`		`@0 07-0053593`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Current pharmaceutical design`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M^pro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M^pros. It is expected that inhibitors targeting CoV M^pros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Médicament @5 01`
C03	`01`	`X`	`ENG`	`@0 Drug @5 01`
C03	`01`	`X`	`SPA`	`@0 Medicamento @5 01`
C03	`02`	`X`	`FRE`	`@0 Cible @5 02`
C03	`02`	`X`	`ENG`	`@0 Target @5 02`
C03	`02`	`X`	`SPA`	`@0 Blanco @5 02`
C03	`03`	`X`	`FRE`	`@0 Ciblage @5 03`
C03	`03`	`X`	`ENG`	`@0 Targeting @5 03`
C03	`03`	`X`	`SPA`	`@0 Blancado @5 03`
C03	`04`	`X`	`FRE`	`@0 Peptidases @2 FE @5 04`
C03	`04`	`X`	`ENG`	`@0 Peptidases @2 FE @5 04`
C03	`04`	`X`	`SPA`	`@0 Peptidases @2 FE @5 04`
C03	`05`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 05`
C03	`05`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 05`
C03	`05`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 05`
C03	`06`	`X`	`FRE`	`@0 Article synthèse @5 06`
C03	`06`	`X`	`ENG`	`@0 Review @5 06`
C03	`06`	`X`	`SPA`	`@0 Artículo síntesis @5 06`
C03	`07`	`X`	`FRE`	`@0 Antiviral @5 07`
C03	`07`	`X`	`ENG`	`@0 Antiviral @5 07`
C03	`07`	`X`	`SPA`	`@0 Antiviral @5 07`
C03	`08`	`X`	`FRE`	`@0 Conception @5 08`
C03	`08`	`X`	`ENG`	`@0 Design @5 08`
C03	`08`	`X`	`SPA`	`@0 Diseño @5 08`
C03	`09`	`X`	`FRE`	`@0 Recherche développement @5 09`
C03	`09`	`X`	`ENG`	`@0 Research and development @5 09`
C03	`09`	`X`	`SPA`	`@0 Investigación desarrollo @5 09`
C03	`10`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 10`
C03	`10`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 10`
C03	`10`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 10`
C03	`11`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 11`
C03	`11`	`X`	`ENG`	`@0 Enzyme inhibitor @5 11`
C03	`11`	`X`	`SPA`	`@0 Inhibidor enzima @5 11`
C03	`12`	`X`	`FRE`	`@0 Structure moléculaire @5 12`
C03	`12`	`X`	`ENG`	`@0 Molecular structure @5 12`
C03	`12`	`X`	`SPA`	`@0 Estructura molecular @5 12`
C07	`01`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`02`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`02`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Virose`
C07	`06`	`X`	`ENG`	`@0 Viral disease`
C07	`06`	`X`	`SPA`	`@0 Virosis`
C07	`07`	`X`	`FRE`	`@0 Infection`
C07	`07`	`X`	`ENG`	`@0 Infection`
C07	`07`	`X`	`SPA`	`@0 Infección`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`09`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`09`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`09`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 036`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000422

Links to Exploration step

Pascal:07-0053593

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design</title>
<author><name sortKey="Haitao Yang" sort="Haitao Yang" uniqKey="Haitao Yang" last="Haitao Yang">HAITAO YANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Laboratory of Biomacromolecules, Institute of Biophysics (IBP), Chinese Academy of Sciences</s1>
<s2>Beijing 100101</s2>
<s3>CHN</s3>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tsinghua-IBP Joint Research Group for Structural Biology, Tsinghua University</s1>
<s2>Beijing 100084</s2>
<s3>CHN</s3>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Bartlam, Mark" sort="Bartlam, Mark" uniqKey="Bartlam M" first="Mark" last="Bartlam">Mark Bartlam</name>
</author>
<author><name sortKey="Zihe Rao" sort="Zihe Rao" uniqKey="Zihe Rao" last="Zihe Rao">ZIHE RAO</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0053593</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 07-0053593 INIST</idno>
<idno type="RBID">Pascal:07-0053593</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000422</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000567</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design</title>
<author><name sortKey="Haitao Yang" sort="Haitao Yang" uniqKey="Haitao Yang" last="Haitao Yang">HAITAO YANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Laboratory of Biomacromolecules, Institute of Biophysics (IBP), Chinese Academy of Sciences</s1>
<s2>Beijing 100101</s2>
<s3>CHN</s3>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Tsinghua-IBP Joint Research Group for Structural Biology, Tsinghua University</s1>
<s2>Beijing 100084</s2>
<s3>CHN</s3>
</inist:fA14>
<country>République populaire de Chine</country>
</affiliation>
</author>
<author><name sortKey="Bartlam, Mark" sort="Bartlam, Mark" uniqKey="Bartlam M" first="Mark" last="Bartlam">Mark Bartlam</name>
</author>
<author><name sortKey="Zihe Rao" sort="Zihe Rao" uniqKey="Zihe Rao" last="Zihe Rao">ZIHE RAO</name>
</author>
</analytic>
<series><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current pharmaceutical design</title>
<title level="j" type="abbreviated">Curr. pharm. des.</title>
<idno type="ISSN">1381-6128</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Coronavirus</term>
<term>Design</term>
<term>Drug</term>
<term>Enzyme inhibitor</term>
<term>Molecular structure</term>
<term>Peptidases</term>
<term>Research and development</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Target</term>
<term>Targeting</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Médicament</term>
<term>Cible</term>
<term>Ciblage</term>
<term>Peptidases</term>
<term>Coronavirus</term>
<term>Article synthèse</term>
<term>Antiviral</term>
<term>Conception</term>
<term>Recherche développement</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Inhibiteur enzyme</term>
<term>Structure moléculaire</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M<sup>pro</sup>
), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M<sup>pro</sup>
s. It is expected that inhibitors targeting CoV M<sup>pro</sup>
s could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1381-6128</s0>
</fA01>
<fA03 i2="1"><s0>Curr. pharm. des.</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>35</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAITAO YANG</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BARTLAM (Mark)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ZIHE RAO</s1>
</fA11>
<fA14 i1="01"><s1>National Laboratory of Biomacromolecules, Institute of Biophysics (IBP), Chinese Academy of Sciences</s1>
<s2>Beijing 100101</s2>
<s3>CHN</s3>
</fA14>
<fA14 i1="02"><s1>Tsinghua-IBP Joint Research Group for Structural Biology, Tsinghua University</s1>
<s2>Beijing 100084</s2>
<s3>CHN</s3>
</fA14>
<fA20><s1>4573-4590</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>26320</s2>
<s5>354000145201350040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>131 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0053593</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Current pharmaceutical design</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARS-CoV infection in many countries. The CoV main protease (M<sup>pro</sup>
), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV M<sup>pro</sup>
s. It is expected that inhibitors targeting CoV M<sup>pro</sup>
s could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Médicament</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Drug</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cible</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Target</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Blanco</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ciblage</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Targeting</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Blancado</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Review</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Conception</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Design</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Diseño</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Recherche développement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Research and development</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Investigación desarrollo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Structure moléculaire</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Molecular structure</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estructura molecular</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>036</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000567 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000567 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0053593
   |texte=   Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design

Drug design targeting the main protease, the Achilles' heel of coronaviruses : SARS-CoV: A scénario of modern drug design

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri